CTOs on the Move

AFB International

www.afbinternational.com

 
AFB International is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Saint Charles, MO. To find more information about AFB International, please visit www.afbinternational.com
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Alternate Health

Alternate Health (CSE: AHG, OTCQB: AHGIF) an international leader in the hemp-derived CBD industry, including extraction, product development and distribution. Alternate Health`s industry-leading software systems provide the platform for the company`s diverse operations, including blockchain tax collection systems, hemp-derived CBD product distribution, extract manufacturing and patient management systems for specialty clinics across North America. Through Alternate Health`s subsidiary, Blaine Labs, the Company is a leader in cGMP medical product manufacturing and distribution, with over 50 product SKUs available from major retailers, including Walmart, Amazon, CVS and Walgreens. Alternate Health`s corporate office is located in Toronto, Canada, with additional offices in Venice, California, and San Antonio, Texas. The Company is well positioned to reinvest internal operating cash flow in its platform and product development over the long term, creating an attractive investment profile for its shareholders.

nutraMetrix, Division of Market America

nutraMetrix, Division of Market America is a Greensboro, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Safeware

Safeware is a safety supply company that provides safety products and technical services to customers in the industrial, government, military, and response markets.

CP Medical

CP Medical is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Geron

We are a biopharmaceutical company developing first-in-class therapies for cancer. Imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. Telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a potent and specific inhibitor of telomerase. Based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or MF, myelodysplastic syndromes, or acute myelogenous leukemia.